{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:17:03Z","timestamp":1788592623148,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Drug Science"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00213-021-05855-2","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T10:08:49Z","timestamp":1620641329000},"page":"1147-1155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21"],"prefix":"10.1007","volume":"239","author":[{"given":"C.","family":"Sakal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lynskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. K.","family":"Schlag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Nutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"5855_CR1","unstructured":"BFarm (2020) Federal Institute for Drugs and Medical Devices. https:\/\/www.bfarm.de\/DE\/Bundesopiumstelle\/Cannabis\/Cannabisagentur\/_node.html [accessed 15\/03\/2021]"},{"issue":"2","key":"5855_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysee","year":"1989","unstructured":"Buysee DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28(2):193\u2013213","journal-title":"Psychiatry Res"},{"key":"5855_CR3","doi-asserted-by":"crossref","unstructured":"Cleeland C (1991) Brief Pain Inventory. Handbook of Pain Assessment. New York: The Guilford Press. pp. 378-382","DOI":"10.1037\/t04175-000"},{"issue":"6","key":"5855_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/jclp.21845","volume":"68","author":"D Conybeare","year":"2012","unstructured":"Conybeare D, Behar E, Solomon A, Newman MG, Borkovec TD (2012) The PTSD Checklist-Civilian Version: reliability, validity, and factor structure in a nonclinical sample. J Clin Psychol 68(6):699\u2013713. https:\/\/doi.org\/10.1002\/jclp.21845","journal-title":"J Clin Psychol"},{"key":"5855_CR5","unstructured":"Couch D (2020) Left behind: the scale of illegal cannabis use for medicinal intent in the UK. https:\/\/www.thecmcuk.org\/left-behind-the-scale-of-illegal-cannabis-use-for-medicinal-intent-in-the-uk\u00a0[accessed 15\/03\/2021]"},{"issue":"1","key":"5855_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hec.3564","volume":"27","author":"NJ Devlin","year":"2018","unstructured":"Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B (2018) Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ (United Kingdom) 27(1):7\u201322. https:\/\/doi.org\/10.1002\/hec.3564","journal-title":"Health Econ (United Kingdom)"},{"key":"5855_CR7","unstructured":"FDA Framework for FDA\u2019s Real-World Evidence Program (2018) FDA Framew. December. www.fda.gov. [accessed 15\/03\/2021]"},{"issue":"5","key":"5855_CR8","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1046\/j.1360-0443.1995.9056072.x","volume":"90","author":"M Gossop","year":"1995","unstructured":"Gossop M, Darke S, Griffiths P et al (1995) The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90(5):607\u2013614. https:\/\/doi.org\/10.1046\/j.1360-0443.1995.9056072.x","journal-title":"Addiction"},{"key":"5855_CR9","doi-asserted-by":"crossref","unstructured":"Haroutounian S, Ratz Y, Ginosar Y, Furmanov K, Saifi F, Meidan R, Davidson E (2016) The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: a prospective open-label study. Clin J Pain 32","DOI":"10.1097\/AJP.0000000000000364"},{"key":"5855_CR10","unstructured":"Health Canada (2015) The Research Institute of the McGill University Health Centre. https:\/\/registrecannabisquebec.com\/en [accessed 15\/03\/2021]"},{"issue":"6","key":"5855_CR11","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40273-018-0623-8","volume":"36","author":"MF Jansen","year":"2018","unstructured":"Jansen MF, Bonsel GJ, Luo N (2018) Is EQ-5D-5L better than EQ-5D-5L? A head-to-head comparison of descriptive systems and value sets from seven countries. Pharmacoeconomics 36(6):675\u2013697","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"5855_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0182162","volume":"12","author":"P Jordan","year":"2017","unstructured":"Jordan P, Shedden-Mora MC, L\u00f6we B (2017) Psychometric analysis of the Generalized Anxiety Disorder scale (GAD-7) in primary care using modern item response theory. PLoS ONE 12(8):1\u201314. https:\/\/doi.org\/10.1371\/journal.pone.0182162","journal-title":"PLoS ONE"},{"issue":"5","key":"5855_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00002508-200409000-00005","volume":"20","author":"S Keller","year":"2004","unstructured":"Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS (2004) Validity of the Brief Pain Inventory for use in documenting. Clin J Pain 20(5):309\u2013318","journal-title":"Clin J Pain"},{"key":"5855_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s42238-020-00038-w","volume":"2","author":"VK Mahabir","year":"2020","unstructured":"Mahabir VK, Merchant JJ, Smith C, Garibaldi A (2020) Medical cannabis use in the United States: a retrospective database study. J Cannabis Res 2:32. https:\/\/doi.org\/10.1186\/s42238-020-00038-w","journal-title":"J Cannabis Res"},{"issue":"1","key":"5855_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2377-14-58","volume":"14","author":"S Meyer-Moock","year":"2014","unstructured":"Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T (2014) Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol 14(1):1\u201310. https:\/\/doi.org\/10.1186\/1471-2377-14-58","journal-title":"BMC Neurol"},{"key":"5855_CR16","unstructured":"Minnesota database (2020) The Minnesota Department of Health. https:\/\/www.health.state.mn.us\/people\/cannabis\/docs\/about\/quarupdates\/oct2020.pdf [accessed 15\/03\/2021]"},{"key":"5855_CR17","unstructured":"National Institute for Heath and Care Excellence (NICE) Cannabis-based medicinal products. NICE Guidelines [NG144]. Published: November 11, 2019. https:\/\/www.nice.org.uk\/guidance\/ng144 [accessed 15\/03\/2021]"},{"key":"5855_CR18","doi-asserted-by":"publisher","unstructured":"Nutt D (2019) Why medical cannabis is still out of patients\u2019 reach-an essay by David Nutt. BMJ 365. https:\/\/doi.org\/10.1136\/bmj.l1903","DOI":"10.1136\/bmj.l1903"},{"key":"5855_CR19","doi-asserted-by":"publisher","first-page":"e038687","DOI":"10.1136\/bmjopen-2020-038687","volume":"10","author":"D Nutt","year":"2020","unstructured":"Nutt D, Bazire S, Phillips LD, Schlag AK (2020) So near yet so far: why won\u2019t the UK prescribe medical cannabis? BMJ Open 10:e038687. https:\/\/doi.org\/10.1136\/bmjopen-2020-038687","journal-title":"BMJ Open"},{"key":"5855_CR20","unstructured":"Pascual (2020) Applications open to supply France with free medical cannabis via pilot program. Marijuana Business Daily. Available at:\u00a0https:\/\/mjbizdaily.com\/applications-open-to-supply-france-with-free-medical-cannabis\/?mc_cid=aa2a155788&mc_eid=cf4b1ce754. Accessed 20 Apr 2021"},{"issue":"1","key":"5855_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12991-018-0203-5","volume":"17","author":"E Rancans","year":"2018","unstructured":"Rancans E, Trapencieris M, Ivanovs R, Vrublevska J (2018) Validity of the PHQ-9 and PHQ-2 to screen for depression in nationwide primary care population in Latvia. Ann Gen Psychiatry 17(1):1\u20138. https:\/\/doi.org\/10.1186\/s12991-018-0203-5","journal-title":"Ann Gen Psychiatry"},{"issue":"1","key":"5855_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.26828\/cannabis.2019.01.005","volume":"2","author":"CA Salazar","year":"2019","unstructured":"Salazar CA, Tomko RL, Akbar SA, Squeglia LM, Mcclure EA (2019) Medical cannabis use among adults in the southeastern United States. Cannabis 2(1):53\u201365","journal-title":"Cannabis"},{"key":"5855_CR23","doi-asserted-by":"crossref","unstructured":"Schlag A (2020) Regimes of medical cannabis: what lessons can be learned for the UK? Med Cannabis Cannabinoids 3:76\u201383","DOI":"10.1159\/000505028"},{"issue":"9","key":"5855_CR24","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1177\/0269881120926677","volume":"34","author":"AK Schlag","year":"2020","unstructured":"Schlag AK, Baldwin DS, Barnes M, Bazire S, Coathup R, Curran HV, McShane R, Phillips LD, Singh I, Nutt DJ (2020) Medical cannabis in the UK: from principle to practice. J Psychopharmacol 34(9):931\u2013937. https:\/\/doi.org\/10.1177\/0269881120926677","journal-title":"J Psychopharmacol"},{"key":"5855_CR25","doi-asserted-by":"publisher","DOI":"10.1089\/can.2019.0096","author":"NJ Schlienz","year":"2020","unstructured":"Schlienz NJ, Scalsky R, Martin EL, Jackson H, Munson J, Strickland JC, Bonn-Miller MO, Loflin M, Vandrey R (2020) A cross-sectional and prospective comparison of medicinal cannabis users and controls on self-reported health. Cannabis Cannabinoid Res. https:\/\/doi.org\/10.1089\/can.2019.0096","journal-title":"Cannabis Cannabinoid Res"},{"issue":"6","key":"5855_CR26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jpain","volume":"16","author":"W Scott","year":"2015","unstructured":"Scott W, McCracken LM (2015) Patients\u2019 impression of change following treatment for chronic pain: global, specific, a single dimension, or many? J Pain 16(6):518\u2013526. https:\/\/doi.org\/10.1016\/j.jpain","journal-title":"J Pain"},{"key":"5855_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1089\/can.2016.0007","volume":"1","author":"M Sexton","year":"2016","unstructured":"Sexton M, Cuttler C, Finnell JS, Mischley LK (2016) A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy. Cannabis Cannabinoid Res 1:131\u2013138. https:\/\/doi.org\/10.1089\/can.2016.0007","journal-title":"Cannabis Cannabinoid Res"},{"issue":"4","key":"5855_CR28","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1037\/1040-3590.17.4.486","volume":"17","author":"EA Storch","year":"2005","unstructured":"Storch EA, Murphy TK, Geffken GR et al (2005) Reliability and validity of the Yale Global Tic Severity Scale. Psychol Assess 17(4):486\u2013491. https:\/\/doi.org\/10.1037\/1040-3590.17.4.486","journal-title":"Psychol Assess"},{"key":"5855_CR29","unstructured":"United Patients\u2019 Alliance (UPA) (2018) UPA Patients\u2019 Survey 2018. [accessed 15\/03\/2021]"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05855-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-021-05855-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05855-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T05:04:45Z","timestamp":1652677485000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-021-05855-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["5855"],"URL":"https:\/\/doi.org\/10.1007\/s00213-021-05855-2","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]},"assertion":[{"value":"6 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CS was clinical director of T21 until September 2020. AKS is head of research at the charity Drug Science. ML is head of data at Drug Science. DJN is chair of Drug Science.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}